(lp0
S'Epirus Biopharmaceuticals Inc : Down, But Perhaps Not Out Insider Financial - Jul 18, 2016 The biosimilar space is poised to become the next billion-dollar subsector of healthcare, and a host of companies are pushing to pick up a piece of the action.'
p1
aS'Epirus Biopharma: A High Risk/High Reward Biosimilar Investment Seeking Alpha - Dec 31, 2014 Many pharmaceutical insiders are convinced that biological drugs or biologics, represent the future of the industry. Unlike traditional small molecule drugs (Lipitor, Prozac, Viagra, etc.'
p2
aS"Why Epirus Biopharmaceuticals Inc  Shares Are Up Nearly 7% Small Cap Exclusive  - Jul 19, 2016 Epirus Biopharmaceuticals Inc  shares rose 6.95% to $0.280 on Monday as investors priced in the potential impact of the company's leadership reshuffle."
p3
aS'EPIRUS Biopharmaceuticals Reports Fourth Quarter and Fiscal Year 2015 ... GlobeNewswire  - Mar 15, 2016 BOSTON, March 15, 2016  -- EPIRUS Biopharmaceuticals, Inc. , a pure-play biosimilar company focused on the global development and commercialization of biosimilar monoclonal antibodies , today reported&nbsp;...'
p4
aS'EPIRUS and Zalicus Complete Merger - Combined Company Will Trade as EPIRUS ... Business Wire  - Jul 15, 2014 BOSTON----EPIRUS Biopharmaceuticals, Inc. , a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, announced today the&nbsp;...'
p5
aS'EPIRUS Biopharma  Enters Livzon Satisfaction Amendment; Files for ... StreetInsider.com - Jul 25, 2016 Item 1.01. Entry into a Material Definitive Agreement and Item 1.02. Termination of a Material Definitive Agreement. On July 15, 2016, EPIRUS Biopharmaceuticals, Inc.   entered into a Settlement Satisfaction&nbsp;...'
p6
aS'EPIRUS Biopharmaceuticals Expands Biosimilar Pipeline and Capabilities Through ... GlobeNewswire  - Sep 9, 2015 BOSTON, Sept. 09, 2015  -- EPIRUS Biopharmaceuticals, Inc. , a biosimilar company focused on the global development and commercialization of biosimilar monoclonal antibodies , today announced an&nbsp;...EPIRUS Acquires Bioceros for $14.1M, Expanding Biosimilar Pipeline - Genetic Engineering & Biotechnology News '
p7
aS'EPIRUS Biopharmaceuticals Initiates Pivotal Global Phase 3 Clinical Study for ... GlobeNewswire  - Feb 9, 2016 BOSTON, Feb. 09, 2016  -- EPIRUS Biopharmaceuticals, Inc. , a pure-play biosimilar company focused on the development and commercialization of biosimilar monoclonal antibodies , today announced the&nbsp;...EPIRUS Biopharma  Commences BOW015 Phase 3 in RA - StreetInsider.com'
p8
aS'EPIRUS Biopharmaceuticals and Polpharma Group Enter Into a Multi-Product ... GlobeNewswire  - Jul 14, 2015 BOSTON, July 14, 2015  -- EPIRUS Biopharmaceuticals, Inc.  and Polpharma Group today announced the signing of a multi-product, multi-region profit-sharing collaboration for select EPIRUS biosimilars, including&nbsp;...Epirus Launches Biosimilars Collaboration with Polpharma - Genetic Engineering & Biotechnology News '
p9
aS"EPIRUS Biopharma  Will Reallocate Resources to Focus on BOW080, BOW070 ... StreetInsider.com - May 9, 2016 EPIRUS Biopharmaceuticals, Inc.  announced reprioritization of the company's pipeline to focus exclusively on developing biosimilars for the treatment of rare diseases."
p10
a.